Trial Profile
Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Polatuzumab vedotin (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 01 Jan 2021 Results assessing safety, pharmacokinetics and preliminary antitumor activity of Polatuzumab-vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma published in the Japanese Journal of Clinical Oncology
- 16 Mar 2019 Results ethnic sensitivity assessment by using data from two phase I and a phase II studies presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 13 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.